Recombinant Hylobates lar Interleukin-2 (IL2)

What is Hylobates lar IL-2 and how does it compare structurally to human IL-2?

Hylobates lar (white-handed gibbon) IL-2 is an immunomodulatory cytokine belonging to the four-alpha-helix bundle family of proteins . Comparative analysis shows that gibbon IL-2 (P60569) exhibits high sequence similarity to human IL-2 (P60568), as both are listed among identical sequences in protein databases . This high conservation reflects the close phylogenetic relationship between gibbons and humans, with gibbons occupying an intermediate position between great apes and monkeys .

Like human IL-2, gibbon IL-2 is primarily produced by activated CD4+ helper T cells and CD8+ cytotoxic T cells . The mature protein structure is essential for its interaction with the heterotrimeric IL-2 receptor, which consists of the IL-2Rα (CD25), IL-2Rβ, and common gamma chain (γc) . This receptor complex mediates signal transduction for various immunological effects, including T cell proliferation, B cell function regulation, and NK cell activation .

What expression systems are available for producing recombinant Hylobates lar IL-2?

Multiple expression systems can be utilized for producing recombinant Hylobates lar IL-2, each offering distinct advantages for different research applications:

These expression systems are referenced in product listings for recombinant Hylobates lar IL-2, indicating their established use in research contexts . The selection of an appropriate expression system should be guided by the specific requirements of the intended application, considering factors such as protein folding, post-translational modifications, and downstream purification requirements.

What bioactivity assays are appropriate for validating recombinant Hylobates lar IL-2?

Validating the bioactivity of recombinant Hylobates lar IL-2 requires multiple complementary assays:

T cell proliferation assays: The gold standard for IL-2 bioactivity assessment involves measuring the proliferation of IL-2-dependent cell lines such as CTLL-2 mouse cytotoxic T cells . Effective concentrations (ED50) typically range from 0.05-0.25 ng/mL for bioactive IL-2 . Higher values may indicate partial loss of functionality.

Lymphokine-activated killer (LAK) cell generation: This assay evaluates the capacity of IL-2 to generate lymphokine-activated killer cells from peripheral blood lymphocytes, with functional LAK activity indicating bioactive IL-2 .

Receptor binding studies: When Recombinant Human IL-2 Ra Fc Chimera is coated at 1 µg/mL, biotinylated IL-2 typically binds with an ED50 of 4-24 ng/mL . Similar assays can be adapted for gibbon IL-2, providing quantitative binding kinetics.

Flow cytometry validation: Functional flow cytometry can confirm binding specificity, demonstrating that the recombinant IL-2 binds to IL-2 receptor-expressing cells and that this binding can be blocked by specific anti-IL-2R antibodies .

These methodologies provide complementary data on both the structural integrity and functional capacity of the recombinant protein.

How should researchers properly reconstitute and store recombinant Hylobates lar IL-2?

Proper handling of recombinant Hylobates lar IL-2 is critical for maintaining bioactivity:

Reconstitution protocol:

• Reconstitute lyophilized protein at 250 μg/mL in 4 mM HCl

• For carrier-free versions, reconstitution in HCl with trehalose is recommended

• Allow complete dissolution before aliquoting

Storage conditions:

• Lyophilized protein: Store at -20°C to -80°C

• Reconstituted protein: Store at -80°C in small aliquots

• Working solutions: Store at 4°C for up to one week

Stability considerations:

• Avoid repeated freeze-thaw cycles which significantly reduce bioactivity

• Use a manual defrost freezer for long-term storage

• When diluting for assays, include carrier protein (e.g., 0.1-1% BSA) to prevent adsorption to plasticware

Following these protocols ensures maximum retention of biological activity and experimental reproducibility.

How can recombinant Hylobates lar IL-2 be structurally modified to enhance specific functions?

Strategic modifications to recombinant Hylobates lar IL-2 can enhance its research utility:

Polylysine extension: Addition of a lysine-rich oligopeptide (e.g., Gly3-(Lys-Lys-Asp)3-Leu-Glu) to the C-terminus of gibbon IL-2 creates a hybrid molecule (IL-2-L) with comparable bioactivity to native IL-2 . This modification makes the molecule more amenable to chemical derivatization while preserving its biological function .

Biotinylation optimization: IL-2-L retains significantly greater bioactivity after biotinylation compared to standard rIL-2 . The biotinylated IL-2-L can simultaneously bind to both cell surface IL-2R and streptavidin, creating a molecular bridge between IL-2R-positive cells and avidin-coupled reagents .

Receptor selectivity engineering: Specific amino acid substitutions can alter the binding profile to different components of the IL-2 receptor complex, potentially creating variants with preferential activity toward certain lymphocyte subpopulations.

These modifications represent advanced research tools that enable more precise manipulation of IL-2-dependent immune responses in experimental systems.

How do antibody-IL-2 complexes selectively target different T cell subsets?

Antibody-IL-2 complexes represent a sophisticated approach to directing IL-2 activity toward specific T cell populations:

Complex formation methodology:

• Mix recombinant IL-2 with specific anti-IL-2 monoclonal antibodies (typically 2.5 μg rIL-2 and 7.5 μg anti-IL-2 mAb)

• Incubate the mixture at 37°C for 30 minutes

• Dilute in sterile PBS for experimental application

Differential immunological effects:

• JES6.1/IL-2 complexes: Selectively stimulate expansion of regulatory T cells (Tregs)

• S4B6/IL-2 complexes: Predominantly induce expansion of CD8+ T cells and to a lesser extent NK cells

The selective targeting occurs because antibody binding to IL-2 affects how the complex interacts with the heterotrimeric IL-2 receptor on different cell types . These differential effects have significant implications for immunotherapy approaches and facilitate the selective study of T cell subset functions in research models.

What are the cross-reactivity considerations when using Hylobates lar IL-2 in different primate model systems?

When utilizing Hylobates lar IL-2 in various primate models, researchers should consider several cross-reactivity factors:

Phylogenetic relationships: The high conservation between primate IL-2 sequences suggests potential cross-reactivity. Gibbon IL-2 shows significant homology with human IL-2 and that of other primates including orangutan (Pongo abelii, H2PE89), chimpanzee (Pan troglodytes, H2QQ44), and bonobo (Pan paniscus, A0A2R9ACE1) .

Receptor compatibility analysis: Cross-species IL-2 activity depends on compatibility with the heterotrimeric IL-2 receptor complex of the target species. Human and mouse IL-2 exhibit cross-species activity , suggesting gibbon IL-2 may also function across species boundaries, though this requires experimental verification.

Functional validation methodologies:

• Perform IL-2-dependent cell proliferation assays using target species' cells

• Assess STAT5 phosphorylation in target species' lymphocytes

• Evaluate specific T cell subset expansion in mixed lymphocyte cultures

Antibody recognition: When detecting IL-2 or measuring its effects in cross-species studies, verify that detection antibodies recognize relevant epitopes in the Hylobates lar IL-2 protein.

These considerations are essential for designing valid comparative immunology experiments and developing relevant primate models for human diseases.

How can researchers study IL-2 quorum sensing mechanisms in Hylobates lar models?

IL-2 quorum sensing represents a feedback mechanism where regulatory T cells sense IL-2 produced by conventional T cells, creating a homeostatic control system. Methodologies for studying this phenomenon in Hylobates lar models include:

Reporter system development: Establish reporter systems similar to those used in mouse models (such as Ki/Ko.GFP/IL-2) to track IL-2 production at the single-cell level . These systems allow visualization of cells that have recently activated the IL-2 locus, revealing regulatory networks.

Quantitative analysis: In mouse models, the percentage of IL-2-producing cells among CD4+ T cells typically ranges from approximately 2% in the presence of IL-2 to 10-15% in the absence of IL-2, with variations across different genetic backgrounds . Similar quantitative parameters should be established for gibbon models.

Mixed chimera experiments: Creating models with varying ratios of IL-2-sufficient and IL-2-deficient cells can reveal how IL-2 availability influences the fraction of IL-2-producing cells . In such systems, when IL-2-competent cells are diluted in an IL-2-deficient environment, the proportion of cells activating the IL-2 locus increases .

In vitro stimulation protocols: Use PMA/ionomycin or anti-CD3 stimulation to assess the proportion of CD4+ T cells capable of producing IL-2, and analyze how this changes with IL-2 availability or T regulatory cell depletion .

These methodologies can elucidate species-specific aspects of IL-2 regulation and T cell homeostasis in Hylobates lar compared to humans and other model organisms.

How can biotinylated Hylobates lar IL-2 be utilized in advanced research applications?

Biotinylated Hylobates lar IL-2 offers versatile research applications leveraging the high-affinity biotin-streptavidin interaction:

Preparation optimization:

• Generate IL-2-L by adding a lysine-rich oligopeptide to the C-terminus of gibbon IL-2

• Perform biotinylation using NHS-biotin conjugation methods

• Purify using size exclusion chromatography

• Validate dual binding to IL-2R and streptavidin

Research applications:

Biotinylated IL-2-L can simultaneously bind to cell surface IL-2R and streptavidin, creating a molecular bridge between IL-2R-positive cells and avidin-coupled reagents . This property facilitates selective labeling and binding of IL-2-responsive cells, with significant potential applications in IL-2-based immunotherapy approaches .

What therapeutic applications of recombinant IL-2 have translational relevance to Hylobates lar studies?

Understanding the therapeutic applications of recombinant IL-2 provides valuable context for Hylobates lar IL-2 research:

Established clinical applications: Recombinant IL-2 has demonstrated efficacy in treating renal cell carcinoma and melanoma, with objective response rates of approximately 15-20% . The median duration of response in renal cell carcinoma is 23 months .

Comparative biology considerations: The high sequence similarity between human and gibbon IL-2 suggests that therapeutic findings may have cross-species relevance, though species-specific differences in receptor distribution and downstream signaling require careful validation.

Targeted delivery systems: The development of polylysine-extended gibbon IL-2 (IL-2-L) with enhanced biotinylation properties offers potential for advanced targeted delivery approaches . Such selective means of labeling and binding IL-2-responsive cells may have substantial practical utility for IL-2-based immunotherapy .

These translational insights highlight the continuing importance of basic research on IL-2 biology across primate species, with potential long-term applications in both human and veterinary medicine.